SCHEMBL4911209

SCHEMBL4911209

CCCc1c(Cn2ccnc2-c2cccc(F)n2)nnc2c1cnn2C

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4912453 0.86 CTSS (0.34) —
SCHEMBL8261644 0.85 ADORA2A (0.34) ADORA2AADORA1
SCHEMBL8258206 0.82 BRD4 (0.32) —
SCHEMBL5886298 0.80 BRD4 (0.32) —
SCHEMBL4161231 0.79 NOS2 (0.33) —
SCHEMBL5886277 0.79 KCNH2 (0.34) ALDH1A1
SCHEMBL4762669 0.78 PDE10A (0.31) —
SCHEMBL4913331 0.77 ALDH1A1 (0.32) ALDH1A1NPSR1
SCHEMBL4763649 0.77 — —
SCHEMBL5783490 0.76 PDE10A (0.33) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132510-A1 Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives NEUROGEN CORPORATION 2008-06-05 — — US disclosed
US-20080132510-A1 Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives NEUROGEN CORPORATION 2008-06-05 — — US disclosed
US-20080132510-A1 Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives NEUROGEN CORPORATION 2008-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132510-A1 Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives GABRR3, GABRA3, GABRR1 ADORA2A 140/4885ADORA1 120/4885ALDH1A1 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback